IP Library Granted Patent US 6,972,168
Granted Patent B2
US 6,972,168 · App. 10/218,864 · Granted Dec 6, 2005

Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,972,168
App. No.
10/218,864
Granted
Dec 6, 2005
Kind
B2
Abstract

The subject invention pertains to compositions and methods for culturing nerve tissue in vitro and nerve grafts produced using such methods. The compositions and methods of the subject invention can be employed to restore the continuity of nerve interrupted by disease, traumatic events or surgical procedures. The invention also concerns methods for promoting repair of damaged nerve tissue using the present compositions and nerve tissue treated according to such methods.

Claims (55)

1. A method for promoting repair of a damaged nerve, the method comprising:

culturing a nerve graft in vitro under predegenerating conditions that remodel the nerve graft and that increase the neurite-promoting activity of the nerve graft when subsequently implanted;

rendering the nerve graft acellular by killing cells in the nerve graft; and

implanting the nerve graft at a site of damage.

2. The method according to claim 1 , wherein said culturing of the nerve graft in vitro is for a period of time that achieves an increase in axon ingress and extent of growth within the nerve graft when subsequently implanted.

3. The method according to claim 1 , wherein the increase in neurite-promoting activity is as determined by an in vitro neurite outgrowth assay of the nerve graft.

4. The method according to claim 3 , wherein the in vitro neurite outgrowth assay comprises a cryoculture assay.

5. The method according to claim 1 , wherein the increase in neurite-promoting activity is as determined by an in vivo neurite outgrowth assay of the nerve graft.

6. The method according to claim 1 , wherein said culturing of the nerve graft in vitro is for a period of time within the range of about 24 hours to about 96 hours.

7. The method according to claim 1 , wherein said culturing of the nerve graft in vitro is for a period of time within the range of about 24 hours to about 72 hours.

8. The method according to claim 1 , wherein said culturing of the nerve graft in vitro is for a period of time within the range of about 24 hours to about 48 hours.

9. The method according to claim 1 , wherein said culturing of the nerve graft in vitro is conducted at a temperature within the range of about 10° C. to about 37° C. a period of time of about 48 hours.

10. The method according to claim 1 , wherein said culturing of the nerve graft in vitro is conducted at a temperature within the range of about 30° C. to about 37° C.

11. The method according to claim 1 , wherein said culturing of the nerve graft in vitro is conducted at a temperature of about 37° C.

12. The method according to claim 1 , wherein rendering the nerve graft acellular by killing cells in the nerve graft comprises a process selected from the group consisting of freeze-killing and chemical treatment.

13. The method according to claim 1 , wherein said method further comprises freezing the nerve graft for storage.

14. The method according to claim 13 , wherein said freezing is carried out after said culturing in vitro.

15. The method according to claim 1 , wherein said culture comprises placing the nerve graft in contact with culture medium.

16. The method according to claim 15 , wherein the culture medium comprises defined medium.

17. The method according to claim 15 , wherein the culture medium comprises defined medium supplemented with serum.

18. The method according to claim 15 , wherein the culture medium comprises undefined medium.

19. The method according to claim 1 , wherein the nerve graft is mammalian tissue.

20. The method according to claim 1 , wherein the nerve graft is mammalian tissue, selected from the group consisting of human tissue, non-human primate tissue, porcine tissue, rodent tissue, and bovine tissue.

21. The method according to claim 1 , wherein the nerve graft is human tissue.

22. The method according to claim 1 , wherein the nerve graft comprises peripheral nerve tissue.

23. The method according to claim 1 , wherein the damaged nerve comprises nerve tissue of the central nervous system.

24. The method according to claim 1 , wherein said method further comprises applying a tissue adhesive to the damaged nerve, or to the nerve graft, or to both the damaged nerve and the nerve graft.

25. The method according to claim 1 , wherein the nerve graft is a terminal nerve graft.

26. The method according to claim 1 , wherein the nerve graft is an interpositional nerve graft.

27. The method according to claim 1 , wherein said method further comprises resecting the damaged nerve prior to said implanting of the nerve graft.

28. The method according to claim 1 , wherein the nerve graft is autologous with the damaged nerve.

29. The method according to claim 1 , wherein the nerve graft is allogeneic with the damaged nerve.

30. The method according to claim 1 , wherein the nerve graft is xenogeneic with the damaged nerve.

31. The method according to claim 1 , wherein said method further comprises conducting an in vitro neurite outgrowth assay of the nerve graft after said culturing.

32. The method according to claim 31 , wherein the in vitro neutrite outgrowth assay comprises a cryoculture assay.

33. The method according to claim 1 , wherein said method further comprises conducting an in vivo neurite outgrowth assay of the nerve graft after said culturing.

34. The method according to claim 1 , wherein the nerve graft comprises peripheral nerve tissue and wherein said implanting results in axonal growth into basal lamina tubes of the nerve graft accompained by recipient-derived Schwann cells, thereby promoting repair of the damaged nerve.

35. The method according to claim 1 , wherein the nerve graft comprises mammalian tissue selected from the group consisting of human tissue, porcine tissue, and bovine tissue.

36. The method according to claim 1 , wherein the nerve graft comprises nerve tissue of the central nervous system.

37. The method according to claim 1 , wherein the damaged nerve comprises nerve tissue of the peripheral nervous system.

38. A method for promoting repair of a damaged nerve, the method comprising:

culturing a nerve graft in vitro under predegenerating conditions that increase the neurite-promoting activity of the nerve graft when subsequently implanted, the conditions comprising a temperature within the range of about 10° C. for a period of time within the range of about 24 hours to about 96 hours;

rendering the nerve graft acellular by killing cells in the nerve graft; and

implanting the nerve graft at a site of damage.

39. The method according to claim 38 , wherein said nerve graft comprises an allograft or xenograft.

40. The method according to claim 38 , wherein said nerve graft comprises human tissue.

41. The method according to claim 38 , wherein said nerve graft comprises procine tissue or bovine tissue.

42. The method according to claim 38 , wherein said nerve graft comprises nerve tissue of the peripheral nervous system.

43. The method according to claim 38 , wherein said nerve graft comprises nerve tissue of the central nervous system.

44. The method according to claim 38 , wherein said nerve graft comprises nerve tissue of the peripheral nervous system.

45. The method according to claim 38 , wherein said damaged nerve comprises nerve tissue of the central nervous system.

46. A method for promoting repair of a damaged nerve, the method comprising:

placing a nerve graft in conditions in vitro that are permissive to the activation and proliferation of cells within the nerve graft, are permissive to the activity of enzymes produced by cells within the nerve graft, are permissive to the degeneration and remodeling of the nerve graft in vitro, and increase the neurite-promoting activity of the nerve graft when subsequently implanted;

rendering the nerve graft acellular by killing cells in the nerve graft; and

implanting the nerve graft at a site of damage.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded May 31, 2018
From: MIDCAP FUNDING IV TRUST; MIDCAP FINANCIAL TRUST
To: AXOGEN CORPORATION; AXOGEN, INC. FORMERLY KNOWN AS LECTEC CORPORATION
Reel/Frame 045952/0283 →
CONFIRMATORY LICENSE Recorded Apr 14, 2017
From: UNIVERSITY OF FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042257/0092 →
SECURITY INTEREST Recorded Nov 1, 2016
From: AXOGEN, INC. FORMERLY KNOWN AS LECTEC CORPORATION; AXOGEN CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 040189/0429 →
SECURITY INTEREST Recorded Nov 1, 2016
From: AXOGEN, INC. FORMERLY KNOWN AS LECTEC CORPORATION; AXOGEN CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 040189/0049 →
RELEASE OF SECURITY INTEREST OF REEL/FRAME 034173/0187 Recorded Oct 27, 2016
From: THREE PEAKS CAPITAL S.A.R.L.
To: AXOGEN CORPORATION; AXOGEN, INC. (FORMERLY KNOWN AS LECTEC CORPORATION)
Reel/Frame 040502/0018 →
SECURITY INTEREST Recorded Nov 14, 2014
From: AXOGEN CORPORATION
To: THREE PEAKS CAPITAL S.A.R.L.
Reel/Frame 034173/0187 →
RELEASE OF SECURITY AGREEMENT Recorded Oct 5, 2012
From: MIDCAP FINANCIAL SBIC, LP
To: AXOGEN, INC.; AXOGEN CORPORATION
Reel/Frame 029087/0774 →
SECURITY AGREEMENT Recorded Sep 30, 2011
From: AXOGEN, INC.; AXOGEN CORPORATION
To: MIDCAP FINANCIAL SBIC, LP
Reel/Frame 027000/0770 →